Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Integrated omics profiling of dextran sodium sulfate-induced colitic mice supplemented with Wolfberry (Lycium barbarum)

Abstract

We used a multi-omics profiling approach to investigate the suppressive effects of 2% Wolfberry (WOL)-enriched diets on dextran sodium sulfate (DSS)-induced colitis in mice. It was observed that in mice fed the WOL diet, the disease activity index, colon shortening, plasma concentrations of matrix metalloproteinase-3 and relative mesenteric fat weight were significantly improved as compared to the DSS group. Results from colon transcriptome and proteome profiles showed that WOL supplementation significantly ameliorated the expression of genes and proteins associated with the integrity of the colonic mucosal wall and colonic inflammation. Based on the hepatic transcriptome, proteome and metabolome data, genes involved in fatty acid metabolism, proteins involved in inflammation and metabolites related to glycolysis were downregulated in WOL mice, leading to lowered inflammation and changes in these molecules may have led to improvement in body weight loss. The integrated nutrigenomic approach thus revealed the molecular mechanisms underlying the ameliorative effect of whole WOL fruit consumption on inflammatory bowel disease.

Introduction

Inflammatory bowel disease (IBD) is a group of debilitating inflammatory disorders that affect the gastrointestinal tract. IBD includes Crohn’s disease (CD) and ulcerative colitis (UC). Affected patients experience various symptoms associated with gut inflammation, ranging from abdominal pain and diarrhea to rectal bleeding and weight loss. Physicians usually recommend using anti-inflammatory steroids or immunosuppressants to reduce inflammation1. Dietary interventions2 using nutraceuticals3, probiotics, prebiotics2; lifestyle interventions and recently, fecal microbiota transplantation4 are commonly used as alternatives to medical therapy in IBD management5,6,7.

Wolfberry (WOL), the fruit of Lycium barbarum (member of Solanceae), is a sweet red berry that has been used traditionally as a medicinal food in China and other Asian countries like Vietnam, Japan and Korea8,9. WOL comprises of various polyphenols10 including phenylpropanoids, coumarins, lignans, flavonoids, isoflavonoids, chlorogenic acid derivatives10. It also consists of carotenoids (zeaxanthin and carotene)11,12, polysaccharides13,14 and small molecules such as betaine15, cerebroside16, β-sitosterol and various vitamins17. Valuable components of WOL include zeaxanthin, a non-provitamin A carotenoid shown to protect the eyes18 and to enhance immune response19,20. Studies have suggested that WOL consumption may have neuroprotective21,22, anti-aging23, prevention of Alzheimer’s Disease22, and immune-boosting properties9,24,25. WOL polysaccharides also have been reported to have anti-diabetic properties26, improve retinopathy in diabetic rats27 and improve diabetic testicular dysfunction28. It also has been documented that WOL polysaccharide fractions can protect against renal damage29 and reduce immunotoxicity30. It has been previously reported that a milk-based WOL preparation can suppress 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis31 and WOL can suppress dextran sulfate sodium (DSS)-induced colitis32.

Although there are many reports on WOL constituents, there are in fact very few studies using whole WOL even though it is often consumed whole in cuisine, dessert or infused in hot water. In this study, we used a nutrigenomics-based multidimensional approach is used to determine the effects of whole WOL nutritional-intervention dietary signals on the status of genes, proteins and metabolites. We sought to identify the dietary signature of WOL interactions in murine hosts and to elucidate potential molecular mechanisms in a DSS-induced colitis mouse model via comprehensive transcriptome, proteome, and metabolome evaluations not only using colon and but also liver tissues, which is an important metabolic powerhouse in the host.

Results

General characteristics

No significant differences were observed in food intake before DSS (CON: 27.0 ± 2.3; DSS: 27.7 ± 4.7; DSSWOL: 24.8 ± 2.3 g) or after DSS administration (CON: 40.6 ± 9.9; DSS: 37.1 ± 7.9; DSSWOL: 32.3 ± 2.3 g). Water intake during the DSS administration period are as follows: CON: 26.5 ± 0.6; DSS: 24.2 ± 1.5; DSSWOL: 24.8 ± 1.2 mL. The DSS intakes of the DSS and DSSWOL mice were thus not significantly different. The mice that were DSS-challenged presented with significant pathological changes, including severe body weight loss, presence of fecal occult blood, and diarrhea, resulting in a significant increase in the DAI compared to the CON group (Fig. 1a).

Fig. 1: General characteristics.
figure1

a The disease activity index (DAI) was calculated by combining the scores of body weight loss, stool consistency, and fecal blood, and then dividing the score by 3. Each score was determined as follows: change in body weight (0: <1%; 1: 1–5%; 2: 5–10%; 3: 10–15%; 4: >15%), fecal blood (0: no fecal blood observed; 2: ++; 4: +++) and stool consistency (0: normal; 2: soft; 4: diarrhea). b Length of colon. c Relative mesenteric fat. d Plasma Mmp3 levels. e Plasma Il6 concentrations. f H&E staining of the colon. All values are the means ± SD (n = 6–7). Data with different letters (a, b, c) are significantly different at p < 0.05 by Dunnett’s test. p value in the bracket is vs. DSS.

WOL supplementation suppressed these pathological conditions of IBD, resulting in a decrease in the DAI values from day 7 to day 9 (Fig. 1a). Mice from the DSS group had significantly shorter colon lengths (Fig. 1b) and lower mesenteric fat weight (Fig. 1c) compared to the control group, and WOL significantly ameliorated these decreases. The plasma Mmp3 (Fig. 1d) levels were significantly increased by DSS administration, and the WOL intervention significantly mitigated these increases. The concentrations of Il6 in the plasma (Fig. 1e) tended to be improved by WOL supplementation.

Colonic microarray analysis

Messenger RNAs for 2189 genes were differentially expressed in the DSS mice compared to the controls. Among these genes, 271 genes were upregulated in DSSWOL and 207 genes were downregulated compared to the DSS (Supplementary Table 1). WOL decreased the gene expression levels of tissue inhibitor of metalloproteinase 1 (Timp1) and chemokines belonging to the chemokine (C–C motif) ligand (Ccl): Ccl1 and Ccl5. In addition, a lower expression level of proinflammatory cytokine of interleukin 1 receptor type 1 (Il1r1) was observed. Other downregulated genes included secreted phosphoprotein 1 (Spp1), haptoglobin (Hp) and prostaglandin-endoperoxide synthase 2 (Ptgs2). Some of the downregulated genes were related to the breakdown of extracellular matrix and remodeling matrix metalloproteinase (MMP), i.e., Mmp3, Mmp13 and Mmp10; cluster of differentiation (Cd163) and Il6, were selected for validation by real-time RT-PCR. DSS significantly upregulated the expressions of Mmp10, Hp, Il6, Mmp3, and Timp1. WOL supplementation significantly attenuated these increases in Hp, Timp1, and Mmp10 and tended to improve these upregulations in Il6, Cd163, and Mmp3 (Fig. 2).

Fig. 2: Colonic mRNA relative expressions of genes related to the breakdown of extracellular matrix and tissue remodeling, inflammation and IBD.
figure2

Mmp3, Mmp10, Mmp13, Timp1, Hp, Il6, and Cd163 were measured by RT-PCR and normalized to Rplp1. All values are the means ± SD (n = 6–7). Data with different letters (a, b, c) are significantly different at p < 0.05 by Dunnett’s test. p value in the bracket is vs. DSS.

Hepatic microarray analysis

In the liver, 12,838 genes were differentially expressed in DSS compared to the controls. In the DSSWOL group, 1630 genes were upregulated and 1793 genes were downregulated compared to the DSS mice (Supplementary Table 2). WOL supplementation decreased the expression of genes for molecules of cancer markers such as serum amyloid A1 (Saa1), c-Jun (Jun), and S100 calcium-binding protein A8 (S100a8). In addition, genes involved in the fatty acid synthesis, i.e., stearoyl-CoA desaturase-1 (Scd1), ELOVL family member 6, elongation of long chain fatty acids (Elovl6), fatty acid synthase (Fas), and NADP-dependent malic enzyme (Me1) were upregulated. The gene expression level of methionine adenosyltransferase II, alpha (Mat2a), which is involved in the methionine-recycling pathway, was decreased. Based on the results of the validation of gene expression by real-time RT-PCR (Fig. 3), DSS significantly regulated the expression of Elovl6, Fas, Jun, Mat2, Me1, Saa1, Scd1, and S100A8, and WOL supplementation significantly affected the expression of these genes—except for Jun and Saa1, on which WOL tended to have a suppressive effect.

Fig. 3: Hepatic mRNA expressions of genes related to fatty acid synthesis and to cancer markers, and genes involved in glycolysis.
figure3

The relative mRNA expressions of Elovl6, Fas, Me1, Scd1, Jun, Saa1, Mat2a, and S100A8 were measured by RT-PCR and normalized to Ppia. All values are the means ± SD (n = 6–7). Data with different letters (a, b, c) are significantly different at p < 0.05 by Dunnett’s test. p value in the bracket is vs. DSS.

Comparative hepatic and colonic proteomics analysis by iTRAQ

We determined the global protein expression in the three groups by using iTRAQ labeling quantitative proteomic technology. We included a 1.2- or 0.8-fold cut-off from unique proteins quantified at the >95% confidence level when classifying proteins as highly up- or downregulated.

In the liver, we identified 222 proteins, of which 58 proteins were downregulated and 75 proteins were upregulated in DSSWOL compared to the DSS group (Supplementary Table 3). WOL supplementation decreased the levels of proteins that are known to be commonly upregulated in IBD patients: calreticulin (Calr)33, serotransferrin (Trfe)34, annexin A5 (Anxa5)35, beta-enolase (Enob)36, transthyretin (Tthy)37, selenium-binding protein 1 (Sbp1)38, and protein-glutamine gamma-glutamyltransferase 2 (Tgm2)39; proteins involved in fibrosis: fibrinogen beta chain (Fibb) and fibrinogen gamma chain (Fibg)40; and inflammation-related proteins: histone H4 (H4), superoxide dismutase [Cu-Zn] (Sodc)41, cystatin-B (Cytb)42, 10-kDa heat shock protein, mitochondrial (Ch10)43, thioredoxin (Thio)44, and alpha-enolase (Enoa)45.

In the colon, we detected a total of 2,111 proteins, of which 271 were upregulated and 217 were downregulated in the DSSWOL group compared to the DSS group (Supplementary Table 4). WOL supplementation increased the levels of several proteins, including trefoil factor 3 (Tff3), a protein involved in intestinal tight junction integrity and mucus protection46; anterior gradient protein 2 homolog (Agr2)47; the anti-inflammation-related protein carboxypeptidase E (Cbpe)48; and a protein related to DNA repair, 40S ribosomal protein S3 (Rs3)49,50.

Compared to the DSS group, the downregulated proteins in the DSSWOL group were: a negative modulator of leukocyte inflammatory responses, tyrosine-protein phosphatase non-receptor type substrate 1 (Shps1)51; a marker protein in IBD patients, isoform S-gicerin of cell surface glycoprotein MUC18 (Muc18)52; an IBD risk factor protein, apolipoprotein E (Apoe)53; neural cell adhesion molecule L1 (L1cam)54; a protein related to inflammation and tissue injury resistance, ceruloplasmin (Ceru)55; two proteins involved in tumor progression, annexin a3 (Anxa3)56,57 and complement C3 (Co3)58; and neutrophil gelatinase-associated lipocalin (Ngal)59.

Plasma and hepatic metabolome evaluation

To evaluate metabolic alteration by WOL consumption, we performed liver and plasma metabolome analyses of the CON, DSS, and DSSWOL groups based on their m/z values and migration times. The numbers of metabolites detected in the liver tissue and plasma were 131 and 117, respectively. Normalized metabolomics data was used for hierarchical clustering for a heatmap representation and further analyzed by a principal component analysis (PCA) using MeV software.

Although no obvious variations among the groups were observed in the heatmap (Fig. 4a, b), distinct clusters were formed among the CON, DSS, and DSSWOL groups (Fig. 4c, d). Ten metabolites in liver (Supplementary Table 5a) and four metabolites (Supplementary Table 5b) in plasma were significantly regulated by DSS administration and subsequently improved by WOL supplementation. These metabolites included hepatic metabolites involved in the pentose phosphate pathway, i.e., glucose-6-phosphate dehydrogenase (G6P) and fructose 6-phosphate (F6P); and in purine metabolism, i.e., adenosine monophosphate (AMP), inosine monophosphate (IMP) and guanosine monophosphate (GMP). The other metabolites were two molecules related to the methionine-recycling pathway, glutathione and S-lactoylglutathione, and a product of collagen degradation, i.e., hydroxyproline. The upregulation of 2-hydroxyisobutyrate, dodecanoate, and arginine was observed in plasma metabolome profiles.

Fig. 4: The normalized tabolomics data were hierarchically clustered on both the metabolite and sample axes for a heatmap representation and further analyzed by PCA using MeV and XLSTAT software.
figure4

No distinct difference among the three groups was observed in the heatmap (a, b) but distinct clusters were formed among CON, DSS, and DSSWOL in the PCA data analysis (c, d) of both plasma and liver metabolites.

Discussion

We comprehensively examined the impact of WOL supplementation on the inflamed colon and liver transcriptome and proteome, as well as the plasma and liver metabolome profiles. Our results revealed that WOL dietary supplementation may ameliorate DSS-induced colonic injury and inflammation and enhance gut barrier defense by maintaining mucosal integrity, as described below. Our findings also revealed modulated metabolic pathways and potential key gene/protein regulatory hubs that may regulate these processes. Our experimental approach of WOL feeding prior to DSS challenge can be regarded as similar to the patterns of the consumption of various food products by IBD patients during a period of fluctuating disease activity60. To our knowledge, this is an unprecedented report of the use of pure whole WOL in IBD using a comprehensive nutrigenomics approach, particularly in UC.

Our colon gene expression data revealed that WOL intervention suppresses colonic inflammation. Inflammatory responses in IBD usually begin with an infiltration of neutrophils and macrophages61, and thereafter a mixture of inflammatory cytokines, including IL6, IL1 and TNF62, is secreted. This results in the production of proteases, free radicals, and metalloproteinases which are responsible for colon shortening, tissue degradation, and lesion development63. In the present study, the global colon gene expression and RT-PCR validation revealed a tendency of downregulation of Il6, and its downstream factors, Mmp10 and Hp, were reduced significantly by WOL intervention. The expression of Hp has been associated with inflammation is also significantly reduced in inflammatory conditions64. The downregulation of proteins related to inflammation and tissue injury (Ceru and Shps1) and the genes Hp, Mmp10, Timp1 in our DSSWOL group suggests that the WOL intervention lowered the extent of inflammation in the colon induced by DSS.

WOL intake preserved the integrity of the mucosal barrier which is an important component of a healthy gut, as it represents the first line of defense between the luminal content and host tissues. A damaged mucosal barrier enables microbial interactions with the colonic mucosa, which can stimulate host innate and inflammatory immune responses. Downregulation of fibrosis-related proteins, i.e., Fibb and Fibg65, and genes of metalloproteinases were observed in DSSWOL mice as compared to DSS. The significantly downregulated expression level of Mmp10 and plasma Mmp3 by WOL intervention could help prevent the degradation of a broad range of extracellular components including proteoglycans, type II, type IV, type IX and type XI collagens, laminin, and fibronectin63, thereby inhibiting the degradation of the mucosal wall that is manifested in IBD patients66.

WOL supplementation also improved mucosal barrier integrity via modulating the expression levels of the protein Tff3, which is commonly expressed in the gastrointestinal tract and in most of the mucosal membranes67,68, is able to maintain the integrity of the tight junctions and maintain intestinal barrier function by protecting the epithelial layer in combination with mucin69. This protein is also related to angiogenesis and anti-apoptosis by its combined action with mucins67. Intestinal goblet cells secrete not only the MUC2 mucin but also a number of typical mucus components including AGR2, and TFF370. The upregulation of Tff3 in the present DSSWOL group indicates that WOL supplementation improved the integrity of the intestinal barrier function and tight junction that had been degraded by DSS administration. The protein Agr2 secreted by epithelial cells plays a vital function in the synthesis of the intestinal mucin Muc2, which is a type of cysteine-rich glycoprotein that develops the mucus gel lining the intestine. Agr2 deficiency is suggested to lead to susceptibility to IBD71. Prior in vivo research also revealed that Agr2 is related to the maintenance of epithelial integrity in a mouse model47. In our present investigation, WOL intervention enhanced not only the expression of Agr2 but also the colonic mucosal defense function in DSS-challenged mice.

Despite a relatively short DSS administration period, WOL intervention improved the expression levels of cancer-related proteins in the colon (Anxa3 and Co3) as well as oncogenic hepatic genes (Saa1, Jun and S100a8) as observed in the DSSWOL mice as compared to the DSS group. It has been reported that 2% of IBD cases progress to colorectal cancer (CRC) and account for 15% of CRC-related deaths. Axelrad et al. and Pedersen et al. also reported that in IBD patients, long-term exposure to chronic inflammation is the primary risk factor for CRC development as well as other types of cancers72,73. By lowering the expression of these cancer-related markers and proteins commonly expressed in IBD patients (Muc18, Apoe, L1cam), WOL intervention might delay the onset of IBD-related CRC.

WOL intake also improved the metabolic pathways involved in glycolysis. During inflammation, numerous immune cells are activated and migrate to inflammatory lesions. Phagocytosis, bacteria-killing and stimulated cell proliferation have high energy demands74. Neutrophils, macrophages, and dendritic cells primarily use glycolytic pathways to obtain energy, whereas B and T cells mainly use amino acids, glucose, and lipids to generate energy during oxidative phosphorylation. Nutrition and oxygen are rapidly limited or depleted in tissues with high inflammatory lesions and elicited immune activities75. Hepatic metabolites involved in glycolysis, i.e., G6P and F6P have been significantly upregulated by WOL supplementation, indicating that WOL plays an active role in glycolytic recovery. A significant upregulation of genes involved in fatty acid metabolism (Fas, Me1, Scd1, and Elovl6) by WOL supplementation as well as the metabolic shifts in glycolysis could have contributed to the improved body weight loss in the DSSWOL mice induced by DSS administration. This observation was in accord with the lowered expressions of inflammatory proteins in the liver, such as H4, Sodc, and Cytb.

Our data also showed that WOL intervention could prevent the onset of any early event prior to IBD. In most cases, an inhibitory effect of DSS treatment on SCD1 in the liver has been characterized as an early event prior to IBD clinical symptoms76. The disruption of intestinal microflora and the release of endotoxins following DSS treatment may contribute to the acceleration of DSS-induced colitis76. Direct downstream targets of endotoxins and bacterial infection include proinflammatory cytokines, such as interleukins and TNFα, which can subdue SCD1 expression. Since we observed that the Il6 expression levels were dramatically upregulated by DSS treatment, it is likely that a portal vein delivery of inflammatory markers from the colon contributes to the suppression of Scd1 expression in the liver. In IBD patients, hepatobiliary manifestations are frequently observed as the gastrointestinal tract and the hepatobiliary system is anatomically close, and due to the mesenteric venous drainage ascending via the portal vein into the liver77. WOL treatment downregulated the colonic expression of Il6, leading to a decrease in cytokines delivered to the liver, thereby resulting in the upregulation of Scd1 and preventing the onset of an early event prior to IBD clinical symptoms.

As demonstrated above, we employed a nutrigenomics approach to obtain evidence-based insights into the effect of whole WOL supplementation on IBD (Fig. 5). The integrated colon transcriptome and proteome profiles also indicated that 2% WOL supplementation in DSS-challenged mice significantly ameliorated inflammation in the colon, which maintained the integrity of the colonic mucosal wall and might have prevented the risk factors leading to the pathogenesis to CRC. The hepatic transcriptome, proteome, and metabolome data showed that in WOL-fed mice, genes involved in fatty acid metabolism, proteins involved in inflammation, and metabolites related to glycolysis were ameliorated, leading to lowered inflammation and could have contributed to the improvements in body weight. Taken together, our findings provide integrated nutrigenomics information regarding the effect of WOL, a traditional Chinese fruit, on a colitic model. Our results can be expected to be impactful, as the daily inclusion of WOL in a diet could be a dietary strategy to maintain gut health and reduce disease severity in mucosal damage-associated pathologies.

Fig. 5
figure5

Schematic summary of the integrated omics profiling of WOL intervention in the DSS-colitic mouse model.

Methods

Animals and dietary treatment

Animal care and treatment were approved based on the institutional ethical guidelines at the University of Tokyo and approved by the animal experiment committee of the Faculty of Agriculture, The University of Tokyo (Approval no. P13–739). Seven-week-old male C57BL6/J mice (Charles River Japan, Tokyo) were housed individually in animal cages in a room with controlled temperature (23 ± 2 °C), humidity (50 ± 10%), and a 12-h light (08:00–20:00) and dark (20:00–08:00) cycle throughout the experimental period. After 3 days’ acclimatization, the mice were divided into three groups of 6–7 mice each with equivalent body weights, and provided with the following diets (Supplementary Table 6a) and drinking water: (1) AIN-93G basal diet and tap water for the course of the entire experiment (controls; CON), (2) AIN-93G basal diet and tap water for 1 week, after which colitis was induced by administering tap water containing 1.5% (w/v) DSS (molecular weight, 40 KDa; MP Biomedicals, Irvine, CA) (the DSS group), and (3) 2% WOL-supplemented AIN-93G basal diet throughout the experimental period, along with colitis induced after 1 week in the same manner as for the DSS group (DSSWOL). The pre-DSS period lasted for 7 days and DSS-drinking water was administered during the last 9 days of the experimental period. WOL powder (Natural Life, Inc., Tokyo) was made from grinding dried WOL. The nutritional content in 100 g dried WOL are as follows: 9.7 g protein, 0.4 g fat, 77.1 g carbohydrate, 45.6 g sugar, 13 g dietary fiber, 7.5 g moisture, and 0.8 g ash. The food intake, water intake, and DSS intake of each group were monitored carefully throughout the experiment.

Evaluation of disease activity index (DAI)

During the DSS challenge, the body weight, stool consistency, and fecal blood were recorded daily as criteria for the DAI78. The DAI was calculated by combining these three scores and then dividing the score by 3. Each score was determined as follows: change in body weight (0: <1%; 1: 1–5%; 2: 5–10%; 3: 10–15%; 4: >15%), fecal blood (0: no fecal blood observed, 2: bleeding mixed with normal feces observed, 4: only blood observed) and stool consistency (0: normal, 2: soft, 4: diarrhea).

Blood collection and tissue harvesting

Mice were sacrificed at the end of the experimental period with sodium pentobarbital followed by bleeding from the carotid artery, and plasma samples were stored at −80 °C after centrifugation (1000 × g, 15 min, 4 °C). The colon length (from the ileocecal junction to the proximal rectum) of each mouse was measured and used as a parameter for colitis severity. Excised colon and liver samples as well as mesenteric adipose tissues were snap-frozen in liquid nitrogen and stored at −80 °C until further analysis.

Biochemical tests

Plasma concentrations of interleukin-(IL)6 and matrix metalloproteinase-3 (MMP3) were measured using enzyme-linked immunosorbent assay (ELISA) kits (Thermo Scientific, Rockford, IL and R&D Systems, Minneapolis, MN, respectively), according to the manufacturer’s instructions.

Total RNA extraction and transcriptome analysis

Total RNA was extracted from the frozen liver and colon samples. Its concentration was determined from the optical density at 260 nm on a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA), and the purity was assessed by determining the A260/A280 ratio79. RNA from each respective group was pooled (n = 6–7), and colonic and hepatic transcriptome evaluations were carried out. We used Affymetrix GeneChip Command Console® software to analyze the gene expression ratios of the DSS versus CON group data and the DSSWOL versus DSS group data. Array images were analyzed with Microarray Suite ver. 5.0 (MAS5) (Affymetrix). Genes whose expressions changed more than 1.2-fold between treatments were considered to be differentially expressed.

Real-time reverse transcription polymerase chain reaction (RT-PCR)

To detect and validate the expression of differentially expressed genes related to inflammation and IBD, we carried out an RT-PCR using the real-time PCR detection system (Takara Bio, Madison, WI, USA)79. Final mixture (12.5 μL) for RT-PCR consisted of 1 × SYBR Premix Ex Taq Mix (Takara), 0.4 μM of each forward and reverse primers and 1 μL of cDNA. Primers were designed using PRIMER3, and their sequences are as detailed in Supplementary Table 6b. Relative mRNA expressions were normalized to 60S acidic ribosomal protein P1 (Rplp1) in the colon and peptidyl-prolyl cis-trans isomerase (Ppia) in the liver. Gene expression data are presented as the fold change of normalized mRNA amounts of each sample compared to those from the DSS group.

Protein preparation, itraq labeling, and nanolc-ms/ms analysis for proteome analysis

Total hepatic and colonic protein were extracted and prepared according to manufacturer’s instructions (AB SCIEX, Framingham, MA). The preparation was then iTRAQ labeled and subjected to nanoscale liquid chromatography coupled to tandem mass spectrometry (nanoLC-MS/MS) analysis. We conducted the protein identification and quantification for iTRAQ samples using ProteinPilot software (ver. 4.0, AB SCIEX) with 95% confidence against switchProt. We used the Paragon Algorithm in the ProteinPilot software for the peptide identification and isoform specific quantification78.

Metabolome analysis

The metabolome profiles were evaluated by extracting metabolites from frozen plasma and liver samples by adding 400 μL of methanol including the internal standards (20 μM each of methionine sulfone and D-camphor-10-sulfonic acid (CSA)) was added to the 40 μL of samples. Next, this mixture was then mixed with 120 μL of ultrapure water and 400 μL of chloroform before centrifuging at 10,000 × g for 3 min at 4 °C. Thereafter, proteins and lipids were removed by transferring the aqueous layer to a centrifugal filter tube (UltrafreeMC-PLHCC 250/pk for Metabolome Analysis, Human Metabolome Technologies). The filtrate was centrifugally concentrated and dissolved in 20 μL of ultrapure water that contained reference compounds (200 μM each of 3-aminopyrrolidine and trimesic acid) immediately before CE-TOFMS analysis80. All CE-TOFMS experiments were performed using the Agilent CE capillary electrophoresis system (Agilent Technologies). Annotation tables were produced from the measurement of standard compounds that were aligned with the datasets according to similar value and normalized migration time. Peak areas were then normalized against those of the internal standards methionine sulfone or CSA for cationic and anionic metabolites, respectively. The concentrations of each metabolite were calculated based on their relative peak areas and concentrations of standard compounds.

Statistical analysis

All data relating to general characteristics, biochemical parameters, relative gene expression, and relative metabolite concentrations are presented as the mean ± standard deviation (SD). We analyzed the data by performing a one-way analysis of variance (ANOVA) and Dunnett’s test (BellCurve for Excel,Social Survey Research Information Co., Ltd). Differences were considered statistically significant at p < 0.05 compared to the DSS group.

Data availability

The authors declare that [the/all other] data supporting the findings of this study are available within the paper (and its supplementary information files). The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. 1.

    Amezaga, A. J. & Van Assche, G. Practical approaches to “top-down” therapies for Crohn’s disease. Curr. Gastroenterol. Rep. 18, 35, (2016).

    PubMed  Google Scholar 

  2. 2.

    Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R. & Rastall, R. A. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat. Rev. Gastroenterol. Hepatol. https://doi.org/10.1038/s41575-019-0173-3 (2019).

  3. 3.

    Uranga, J. A., Lopez-Miranda, V., Lombo, F. & Abalo, R. Food, nutrients and nutraceuticals affecting the course of inflammatory bowel disease. Pharmacol. Rep. 68, 816–826 (2016).

    CAS  PubMed  Google Scholar 

  4. 4.

    Pigneur, B. & Sokol, H. Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail. Mucosal Immunol. 9, 1360–1365, (2016).

    CAS  PubMed  Google Scholar 

  5. 5.

    Donnellan, C. F., Yann, L. H. & Lal, S. Nutritional management of Crohn’s disease. Ther. Adv. Gastroenterol. 6, 231–242 (2013).

    Google Scholar 

  6. 6.

    Richards, J. L., Yap, Y. A., McLeod, K. H., Mackay, C. R. & Marino, E. Dietary metabolites and the gut microbiota: an alternative approach to control inflammatory and autoimmune diseases. Clin. Transl. Immunol. 5, e82 (2016).

    Google Scholar 

  7. 7.

    Triantafillidis, J. K., Triantafyllidi, A., Vagianos, C. & Papalois, A. Favorable results from the use of herbal and plant products in inflammatory bowel disease: evidence from experimental animal studies. Ann. Gastroenterol. 29, 268–281 (2016).

    PubMed  PubMed Central  Google Scholar 

  8. 8.

    Gao, Y., Wei, Y., Wang, Y., Gao, F. & Chen, Z. Lycium Barbarum: a traditional Chinese herb and a promising anti-aging agent. Aging Dis. 8, 778–791 (2017).

    PubMed  PubMed Central  Google Scholar 

  9. 9.

    Potterat, O. Goji (Lycium barbarum and L. chinense): phytochemistry, pharmacology and safety in the perspective of traditional uses and recent popularity. Planta Med. 76, 7–19 (2010).

    CAS  PubMed  Google Scholar 

  10. 10.

    Zhou, Z.-Q. et al. Polyphenols from wolfberry and their bioactivities. Food Chem. 214, 644–654 (2017).

    CAS  PubMed  Google Scholar 

  11. 11.

    Inbaraj, B. S. et al. Determination of carotenoids and their esters in fruits of Lycium barbarum Linnaeus by HPLC–DAD–APCI–MS. J. Pharm. Biomed. Anal. 47, 812–818 (2008).

    CAS  PubMed  Google Scholar 

  12. 12.

    Peng, Y. et al. Quantification of zeaxanthin dipalmitate and total carotenoids in lycium fruits (Fructus Lycii). Plant Foods Hum. Nutr. 60, 161–164 (2005).

    CAS  PubMed  Google Scholar 

  13. 13.

    Xie, J. et al. Effects of polysaccharides in Lycium Barbarum berries from different regions of China on macrophages function and their correlation to the glycosidic linkages. J. Food Sci. 82, 2411–2420 (2017).

    CAS  PubMed  Google Scholar 

  14. 14.

    Cheng, J. et al. An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides. Drug Des., Dev. Ther. 9, 33–78 (2015).

    CAS  Google Scholar 

  15. 15.

    Shin, Y. G., Cho, K. H., Kim, J. M., Park, M. K. & Park, J. H. Determination of betaine in Lycium chinense fruits by liquid chromatography–electrospray ionization mass spectrometry. J. Chromatogr. A 857, 331–335 (1999).

    CAS  PubMed  Google Scholar 

  16. 16.

    Kim, S. Y. et al. A novel cerebroside from lycii fructus preserves the hepatic glutathione redox system in primary cultures of rat hepatocytes. Biol. Pharm. Bull. 22, 873–875 (1999).

    CAS  PubMed  Google Scholar 

  17. 17.

    Toyoda-Ono, Y. et al. 2-O-(β-d-Glucopyranosyl)ascorbic acid, a novel ascorbic acid analogue isolated from lycium fruit. J. Agric. Food Chem. 52, 2092–2096 (2004).

    CAS  PubMed  Google Scholar 

  18. 18.

    Yu, M., Yan, W. & Beight, C. Lutein and zeaxanthin isomers protect against light-induced retinopathy via decreasing oxidative and endoplasmic reticulum stress in BALB/cJ mice. Nutrients 10, https://doi.org/10.3390/nu10070842 (2018).

  19. 19.

    Li, S. Y. et al. Lycium barbarum polysaccharides reduce neuronal damage, blood-retinal barrier disruption and oxidative stress in retinal ischemia/reperfusion injury. PLoS ONE 6, e16380 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Zhou, J. et al. Effects of lycium barbarum polysaccharides on apoptosis, cellular adhesion, and oxidative damage in bone marrow mononuclear cells of mice exposed to ionizing radiation injury. Biomed. Res. Int. 2016, 4147879 (2016).

    PubMed  PubMed Central  Google Scholar 

  21. 21.

    Ho, Y.-S. et al. Characterizing the neuroprotective effects of alkaline extract of Lycium barbarum on β-amyloid peptide neurotoxicity. Brain Res. 1158, 123–134 (2007).

    CAS  PubMed  Google Scholar 

  22. 22.

    Yu, M.-S. et al. Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against β-amyloid peptide neurotoxicity. Exp. Gerontol. 40, 716–727 (2005).

    PubMed  Google Scholar 

  23. 23.

    Chang, R. C.-C. & So, K.-F. Use of anti-aging herbal medicine, lycium barbarum, against aging-associated diseases. What do we know so far? Cell. Mol. Neurobiol. 28, 643–652 (2008).

    CAS  PubMed  Google Scholar 

  24. 24.

    Zhang, Q. et al. Composition of Lycium barbarum polysaccharides and their apoptosis-inducing effect on human hepatoma SMMC-7721 cells. Food Nutr. Res. 59, 28696 (2015).

    PubMed  Google Scholar 

  25. 25.

    Gan, L., Zhang, S. H., Liu, Q. & Xu, H. B. A polysaccharide-protein complex from Lycium barbarum upregulates cytokine expression in human peripheral blood mononuclear cells. Eur. J. Pharm. 471, 217–222 (2003).

    CAS  Google Scholar 

  26. 26.

    Xia, H. et al. An untargeted metabolomics approach reveals further insights of Lycium barbarum polysaccharides in high fat diet and streptozotocin-induced diabetic rats. Food Res. Int. 116, 20–29 (2019).

    CAS  PubMed  Google Scholar 

  27. 27.

    Yao, Q. et al. Lycium barbarum polysaccharides improve retinopathy in diabetic sprague-dawley rats. Evid.-Based Complementary Alternative Med. 2018, 7943212 (2018).

    Google Scholar 

  28. 28.

    Shi, G. J. et al. Lycium barbarum polysaccharide attenuates diabetic testicular dysfunction via inhibition of the PI3K/Akt pathway-mediated abnormal autophagy in male mice. Cell Tissue Res. 374, 653–666 (2018).

    CAS  PubMed  Google Scholar 

  29. 29.

    Li, J. et al. Protective effects of fraction 4a of polysaccharides isolated from Lycium barbarum against KBrO3-induced renal damage in rats. Food Funct. 8, 2566–2572 (2017).

    CAS  PubMed  Google Scholar 

  30. 30.

    Deng, X. et al. Fraction from lycium barbarum polysaccharides reduces immunotoxicity and enhances antitumor activity of doxorubicin in mice. Integr. Cancer Therapies 17, 860–866 (2018).

    CAS  Google Scholar 

  31. 31.

    Philippe, D. et al. Anti-inflammatory effects of Lacto-Wolfberry in a mouse model of experimental colitis. World J. Gastroenterol. 18, 5351–5359 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Kang, Y., Xue, Y., Du, M. & Zhu, M. J. Preventive effects of Goji berry on dextran-sulfate-sodium-induced colitis in mice. J. Nutr. Biochem 40, 70–76 (2017).

    CAS  PubMed  Google Scholar 

  33. 33.

    Watanabe, K. et al. Anti-calreticulin antibodies in patients with inflammatory bowel disease. Fukushima J. Med. Sci. 52, 1–11 (2006).

    CAS  PubMed  Google Scholar 

  34. 34.

    Bennike, T., Birkelund, S., Stensballe, A. & Andersen, V. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J. Gastroenterol. 20, 3231–3244 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Fayad, R., Brand, M. I., Stone, D., Keshavarzian, A. & Qiao, L. Apoptosis resistance in ulcerative colitis: high expression of decoy receptors by lamina propria T cells. Eur. J. Immunol. 36, 2215–2222 (2006).

    CAS  PubMed  Google Scholar 

  36. 36.

    Kwon, S. C. et al. Proteomic analysis of colonic mucosal tissue from tuberculous and ulcerative colitis patients. Korean J. Physiol. Pharmacol. 16, 193–198 (2012).

    PubMed  PubMed Central  Google Scholar 

  37. 37.

    Hansen, J. J., Holt, L. & Sartor, R. B. Gene expression patterns in experimental colitis in IL-10-deficient mice. Inflamm. bowel Dis. 15, 890–899 (2009).

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Speckmann, B. & Steinbrenner, H. Selenium and selenoproteins in inflammatory bowel diseases and experimental colitis. Inflamm. bowel Dis. 20, 1110–1119 (2014).

    PubMed  Google Scholar 

  39. 39.

    Rodriguez-Pineiro, A. M. & Johansson, M. E. The colonic mucus protection depends on the microbiota. Gut microbes 6, 326–330 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Boonla, C. et al. Inflammatory and fibrotic proteins proteomically identified as key protein constituents in urine and stone matrix of patients with kidney calculi. Clin. Chim. Acta 429, 81–89 (2014).

    CAS  PubMed  Google Scholar 

  41. 41.

    Tsaprouni, L. G., Ito, K., Powell, J. J., Adcock, I. M. & Punchard, N. Differential patterns of histone acetylation in inflammatory bowel diseases. J. Inflamm. 8, 1 (2011).

    CAS  Google Scholar 

  42. 42.

    Jang, S. W. et al. Parasitic helminth cystatin inhibits DSS-induced intestinal inflammation via IL-10(+)F4/80(+) macrophage recruitment. Korean J. Parasitol. 49, 245–254 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Hauet-Broere, F. et al. Heat shock proteins induce T cell regulation of chronic inflammation. Ann. Rheum. Dis. 65(Suppl 3), iii65–68 (2006).

    PubMed  PubMed Central  Google Scholar 

  44. 44.

    El Hadri, K. et al. Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arteriosclerosis, Thrombosis, Vasc. Biol. 32, 1445–1452 (2012).

    CAS  Google Scholar 

  45. 45.

    Vermeulen, N. et al. Anti-alpha-enolase antibodies in patients with inflammatory Bowel disease. Clin. Chem. 54, 534–541 (2008).

    CAS  PubMed  Google Scholar 

  46. 46.

    Xu, L. F., Teng, X., Guo, J. & Sun, M. Protective effect of intestinal trefoil factor on injury of intestinal epithelial tight junction induced by platelet activating factor. Inflammation 35, 308–315 (2012).

    CAS  PubMed  Google Scholar 

  47. 47.

    Zheng, W. et al. Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes Immun. 7, 11–18 (2006).

    CAS  PubMed  Google Scholar 

  48. 48.

    Bar, F. et al. Carboxypeptidase E modulates intestinal immune homeostasis and protects against experimental colitis in mice. PloS ONE 9, e102347 (2014).

    PubMed  PubMed Central  Google Scholar 

  49. 49.

    Yadavilli, S. et al. Ribosomal protein S3: a multi-functional protein that interacts with both p53 and MDM2 through its KH domain. DNA repair 8, 1215–1224 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Wang, W. et al. Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications. Med. Res. Rev. 35, 225–285 (2015).

    PubMed  Google Scholar 

  51. 51.

    Zen, K. et al. Inflammation-induced proteolytic processing of the SIRPalpha cytoplasmic ITIM in neutrophils propagates a proinflammatory state. Nat. Commun. 4, 2436 (2013).

    PubMed  PubMed Central  Google Scholar 

  52. 52.

    Hume, G. E. et al. Altered Expression of Angiotensinogen and Mediators of Angiogenesis in Ileal Crohn’s Disease. J. Gastrointest. Liver Dis. 25, 39–48 (2016).

    Google Scholar 

  53. 53.

    Al-Meghaiseeb, E. S. et al. Genetic association of apolipoprotein E polymorphisms with inflammatory bowel disease. World J. Gastroenterol. 21, 897–904 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Sebens, S. & Schafer, H. How two sites of inflammation promote carcinogenesis: The role of macrophages in inflammation associated carcinogenesis. Oncoimmunology 1, 951–953 (2012).

    PubMed  PubMed Central  Google Scholar 

  55. 55.

    Bakhautdin, B. et al. Protective role of macrophage-derived ceruloplasmin in inflammatory bowel disease. Gut 62, 209–219 (2013).

    CAS  PubMed  Google Scholar 

  56. 56.

    Pan, Q. Z. et al. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Mol. Carcinogenesis 54, 598–607 (2015).

    CAS  Google Scholar 

  57. 57.

    Mussunoor, S. & Murray, G. I. The role of annexins in tumour development and progression. J. Pathol. 216, 131–140 (2008).

    CAS  PubMed  Google Scholar 

  58. 58.

    Ning, C. et al. Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1beta/IL-17A axis. Mucosal Immunol. 8, 1275–1284 (2015).

    CAS  PubMed  Google Scholar 

  59. 59.

    Moschen, A. R. et al. Lipocalin 2 protects from inflammation and tumorigenesis associated with gut microbiota alterations. Cell Host Microbe 19, 455–469 (2016).

    CAS  PubMed  Google Scholar 

  60. 60.

    Zallot, C. et al. Dietary beliefs and behavior among inflammatory bowel disease patients. Inflamm. Bowel Dis. 19, 66–72 (2013).

    PubMed  Google Scholar 

  61. 61.

    Hanauer, S. Inflammatory bowel disease epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 12, S3–9 (2006).

    PubMed  Google Scholar 

  62. 62.

    Podolsky, D. Inflammatory Bowel Disease. N. Engl. J. Med. 347, 417–429 (2002).

    CAS  PubMed  Google Scholar 

  63. 63.

    Stetler-Stevenson, W. Type IV collagenase in tumour invasion and metastasis. Cancer Metastasis Rev. 9, 289–303 (1990).

    CAS  PubMed  Google Scholar 

  64. 64.

    Galicia, G. & Ceuppens, J. Haptoglobin function and regulation in autoimmune diseases, acute phase proteins - Regulation and functions of acute phase proteins, (ed. Veas, F.) 229–246 (IntechOpen, 2011). https://doi.org/10.5772/22483.

  65. 65.

    Wypasek, E. et al. Fibrinogen beta-chain -C148T polymorphism is associated with increased fibrinogen, C-reactive protein, and interleukin-6 in patients undergoing coronary artery bypass grafting. Inflammation 35, 429–435 (2012).

    CAS  PubMed  Google Scholar 

  66. 66.

    Bailey, C. et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn’s disease and normal intestine. J. Clin. Pathol. 47, 113–116 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Aamann, L., Vestergaard, E. M. & Gronbaek, H. Trefoil factors in inflammatory bowel disease. World J. Gastroenterol. 20, 3223–3230 (2014).

    PubMed  PubMed Central  Google Scholar 

  68. 68.

    Podolsky, D. K. et al. Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J. Biol. Chem. 268, 6694–6702 (1993).

    CAS  PubMed  Google Scholar 

  69. 69.

    Kindon, H., Pothoulakis, C., Thim, L., Lynch-Devaney, K. & Podolsky, D. K. Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. Gastroenterology 109, 516–523 (1995).

    CAS  PubMed  Google Scholar 

  70. 70.

    Pelaseyed, T. et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol. Rev. 260, 8–20 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  71. 71.

    Park, S. W. et al. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc. Natl Acad. Sci. USA 106, 6950–6955 (2009).

    CAS  PubMed  Google Scholar 

  72. 72.

    Axelrad, J. et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin. Gastroenterol. Hepatol. 14, 58–64 (2016).

    CAS  PubMed  Google Scholar 

  73. 73.

    Pedersen, N. et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am. J. Gastroenterol. 105, 1480–1487 (2010).

    PubMed  Google Scholar 

  74. 74.

    Borregaard, N. & Herlin, T. Energy metabolism of human neutrophils during phagocytosis. J. Clin. Investig. 70, 550–557 (1982).

    CAS  PubMed  Google Scholar 

  75. 75.

    Kominsky, D. J., Campbell, E. L. & Colgan, S. P. Metabolic shifts in immunity and inflammation. J. Immunol. 184, 4062–4068 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  76. 76.

    Chen, C. et al. Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab. 7, 135–147 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  77. 77.

    Toedter, G. et al. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy. Inflamm. Bowel Dis. 18, 1399–1410 (2012).

    PubMed  Google Scholar 

  78. 78.

    Jia, H. et al. Multi-faceted integrated omics analysis revealed parsley (Petroselinum crispum) as a novel dietary intervention in dextran sodium sulphate induced colitic mice. J. Funct. Foods 11, 438–448 (2014).

    CAS  Google Scholar 

  79. 79.

    Jia, H. et al. Coffee intake mitigated inflammation and obesity-induced insulin resistance in skeletal muscle of high-fat diet-induced obese mice. Genes Nutr. 9, 389 (2014).

    PubMed  PubMed Central  Google Scholar 

  80. 80.

    Murakami, S. et al. The consumption of bicarbonate-rich mineral water improves glycemic control. Evid.-Based Complementary Alternative Med. 2015, 824395 (2015).

    Google Scholar 

Download references

Acknowledgements

This work was supported by a Grant-in-Aid (18K11095) from the Japan Society for the Promotion of Science (JSPS).

Author information

Affiliations

Authors

Contributions

H.J. and W.A. designed the research; H.J. and W.A. conducted the animal experiments; W.L. analyzed the proteome data; W.A., S.F., and M.T. analyzed the metabolome data; L.O. and M.H. performed the statistical analysis; W.A. and H.J. wrote the paper. H.K. revised the paper and had primary responsibility for the final content. All authors read and approved the final manuscript. W.A. and H.J. contributed equally to this work.

Corresponding authors

Correspondence to Huijuan Jia or Hisanori Kato.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Aw, W., Jia, H., Lyu, W. et al. Integrated omics profiling of dextran sodium sulfate-induced colitic mice supplemented with Wolfberry (Lycium barbarum). npj Sci Food 4, 5 (2020). https://doi.org/10.1038/s41538-020-0065-5

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing